Trial Enrollment Watch — Week of July 06, 2026

Week in Numbers

Public ClinicalTrials.gov records this week show 55 aggregate distress signals (delays, suspensions, or under-enrollment flags) across all therapeutic areas, alongside 223 overdue-results trials newly indexed by our rolling registry scan — studies completed more than a year ago with no results posted — and 64 newly registered trials. Rare disease and oncology remain the two largest categories by volume in every dimension we track, which is consistent with the broader pipeline mix rather than a new trend.

Where the Slippage Is

By therapeutic area, distress signals concentrate in rare disease (23) and oncology (16), followed by endocrine (6). Cardiovascular, respiratory, immunology, and neurology each sit in the low single digits this week. The overdue-results backlog additions follow a similar pattern, with rare disease (117) and oncology (50) far outpacing other areas, and neurology (16) and endocrine (10) trailing behind. The concentration of the overdue-results backlog in rare disease is worth watching: a large backlog of unposted results alongside continued new starts suggests operational bandwidth in this space is being stretched across an expanding trial base, not that any single program is underperforming.

Notable New Registrations

NCT07673029 — GeneQuantum Healthcare (Suzhou), HER2-positive Breast Cancer, Phase 3, 70 sites
NCT07674654 — Kallyope Inc., Acute Migraine, Phase 3, 120 sites
NCT07675135 — Harmony Biosciences, EDS/Cataplexy/Fatigue/Narcolepsy, Phase 3, 14 sites
NCT07678775 — ML Bio Solutions, LGMD Type 2I, Phase 3, 20 sites
NCT07680790 — Bristol-Myers Squibb, Non-Small Cell Lung Cancer, Phase 3, 180 sites
NCT07684898 — Hangzhou Gensciences, Severe Hemophilia A, Phase 3, 19 sites
NCT07678827 — Alvogen Korea, ADHD, Phase 3, site count not yet published

Site Selection Takeaway

Trials launching with

---

About these numbers. Individual trial facts — NCT IDs, sponsors, phases, site counts — come directly from ClinicalTrials.gov and can be verified there. Weekly totals, therapeutic-area breakdowns, enrollment-distress flags, and the overdue-results index are produced by Eichor's own daily registry scans and analysis heuristics; they are our measurements of public data, not statistics published by ClinicalTrials.gov or FDA. The 3,000-plus overdue-trials benchmark references FDA's March 2026 compliance reminders to 2,200-plus sponsors (FDA announcement). How we're built · How findings are signed.

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →
Launch offer through July 31: first full site unlock free — one per company.